CYT RSI Chart
Last 90 days
-3.2%
Trailing 12 Months
44.0%
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Mar 20, 2024 | leonard braden michael | bought | 503,238 | 2.95 | 170,589 | - |
Mar 18, 2024 | leonard braden michael | bought | 342,469 | 3.01 | 113,777 | - |
Mar 04, 2024 | renschler markus md | acquired | 10,653 | 1.69 | 6,304 | president and ceo |
Mar 04, 2024 | gaiero david g | acquired | 4,010 | 1.69 | 2,373 | chief financial officer |
Feb 29, 2024 | renschler markus md | acquired | 24,350 | 1.60791 | 15,144 | president and ceo |
Feb 29, 2024 | gaiero david g | acquired | 13,462 | 1.68594 | 7,985 | chief financial officer |
Feb 14, 2024 | george jean | acquired | 23,913 | 1.69 | 14,150 | - |
Feb 09, 2024 | sands stephen h. | acquired | 20,498 | 1.69 | 12,129 | - |
Feb 08, 2024 | thero john f | acquired | 21,679 | 1.69 | 12,828 | - |
Feb 06, 2024 | zakrzewski joseph s | acquired | 23,913 | 1.69 | 14,150 | - |
Which funds bought or sold CYT recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Apr 25, 2024 | Lindbrook Capital, LLC | unchanged | - | -60.00 | 6,038 | -% |
Apr 24, 2024 | BML Capital Management, LLC | added | 12.43 | 1,118,680 | 10,998,700 | 7.25% |
Mar 11, 2024 | VANGUARD GROUP INC | added | 7.27 | 269,854 | 2,089,670 | -% |
Feb 26, 2024 | Virtu Financial LLC | sold off | -100 | -228,000 | - | -% |
Feb 15, 2024 | JANE STREET GROUP, LLC | new | - | 126,470 | 126,470 | -% |
Feb 14, 2024 | Royal Bank of Canada | new | - | 16,000 | 16,000 | -% |
Feb 14, 2024 | STATE STREET CORP | unchanged | - | 9,230 | 140,305 | -% |
Feb 14, 2024 | CANTOR FITZGERALD, L. P. | sold off | -100 | -376,289 | - | -% |
Feb 14, 2024 | CSS LLC/IL | reduced | -2.97 | 6,258 | 168,291 | 0.01% |
Feb 14, 2024 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | new | - | 99,712 | 99,712 | -% |
Unveiling Cyteir Therapeutics, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Cyteir Therapeutics, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 41.2B | 6.8B | -8.75 | 6.02 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 18.0B | 1.8B | -41 | 9.87 | ||||
BMRN | 15.4B | 2.5B | 74.73 | 6.21 | ||||
INCY | 11.6B | 3.7B | 19.41 | 3.14 | ||||
MID-CAP | ||||||||
APLS | 6.0B | 396.6M | -11.37 | 15.16 | ||||
BBIO | 4.4B | - | -6.7 | 60.35 | ||||
AXSM | 3.4B | 270.6M | -14.22 | 12.57 | ||||
ACAD | 2.8B | 726.4M | -44.9 | 3.79 | ||||
ARWR | 2.7B | 240.7M | -9.23 | 12.18 | ||||
SMALL-CAP | ||||||||
CPRX | 1.8B | 398.2M | 24.58 | 4.41 | ||||
NVAX | 569.6M | 983.7M | -1.05 | 0.58 | ||||
CRBP | 361.2M | 881.7K | -8.1 | 466.16 | ||||
INO | 247.0M | 4.9M | -1.83 | 50.76 | ||||
IBIO | 6.1M | 2.1M | -0.22 | 2.14 |
Cyteir Therapeutics, Inc. News
Balance Sheet | ||||||||||||
Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2020Q4 |
Assets | -2.5% | 131 | 134 | 139 | 153 | 162 | 174 | 186 | 195 | 206 | 202 | - |
Current Assets | -2.4% | 131 | 134 | 138 | 149 | 157 | 170 | 181 | 193 | 204 | 200 | 12.00 |
Cash Equivalents | -3.3% | 129 | 134 | 137 | 147 | 154 | 166 | 177 | 190 | 200 | 199 | 11.00 |
Net PPE | -51.2% | 0.00 | 0.00 | 0.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 1.00 | 1.00 |
Liabilities | -9.4% | 6.00 | 7.00 | 4.00 | 7.00 | 8.00 | 11.00 | 11.00 | 8.00 | 8.00 | 8.00 | 4.00 |
Current Liabilities | -9.3% | 6.00 | 7.00 | 4.00 | 5.00 | 6.00 | 9.00 | 9.00 | 8.00 | 8.00 | 7.00 | 3.00 |
Shareholder's Equity | -2.2% | 125 | 128 | 135 | 146 | 154 | 164 | 175 | 187 | 198 | 194 | - |
Retained Earnings | -2.2% | -162 | -159 | -150 | -138 | -129 | -118 | -106 | -92.05 | -80.24 | -68.50 | -49.93 |
Additional Paid-In Capital | 0.3% | 288 | 287 | 286 | 284 | 283 | 282 | 281 | 279 | 278 | 262 | 2.00 |
Shares Outstanding | 0.3% | 36.00 | 36.00 | 36.00 | 36.00 | 35.00 | 35.00 | 35.00 | 35.00 | 14.00 | 2.00 | 2.00 |
Cashflow (Quarterly) | |||||||||||||||
Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 |
Cashflow From Operations | -9.8% | -4,556 | -4,149 | -10,167 | -6,917 | -12,567 | -10,880 | -12,168 | -9,617 | -12,930 | -7,111 | -6,374 | - | - | - |
Share Based Compensation | -22.8% | 599 | 776 | 1,042 | 869 | 1,193 | 1,365 | 1,255 | 1,133 | 1,072 | 772 | 488 | - | 135 | 107 |
Cashflow From Investing | -100.0% | - | 153 | 150 | - | -10.00 | -111 | -191 | -503 | -394 | -114 | -178 | - | - | - |
Cashflow From Financing | -61.7% | 164 | 428 | 103 | 147 | 71.00 | 5.00 | 19.00 | 21.00 | 14,509 | 121,667 | 79,809 | - | - | - |
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Operating expenses: | ||||
Research and development | $ 2,676 | $ 8,272 | $ 17,391 | $ 27,154 |
General and administrative | 2,495 | 3,487 | 10,809 | 10,963 |
Total operating expenses | 5,171 | 11,759 | 28,200 | 38,117 |
Loss from operations | (5,171) | (11,759) | (28,200) | (38,117) |
Other income (expense): | ||||
Interest income | 1,639 | 714 | 4,385 | 849 |
Loss on disposal of property and equipment | (925) | |||
Gain on lease terminations and modification | 318 | |||
Total other income (expense) | 1,639 | 714 | 3,778 | 849 |
Net loss | $ (3,532) | $ (11,045) | $ (24,422) | $ (37,268) |
Net loss per share--basic | $ (0.10) | $ (0.31) | $ (0.68) | $ (1.06) |
Net loss per share--diluted | $ (0.10) | $ (0.31) | $ (0.68) | $ (1.06) |
Weighted-average common stock outstanding--basic | 36,030,474 | 35,329,137 | 35,647,202 | 35,283,454 |
Weighted-average common stock outstanding--diluted | 36,030,474 | 35,329,137 | 35,647,202 | 35,283,454 |
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands | Sep. 30, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 129,242 | $ 147,120 |
Prepaid expenses and other current assets | 1,401 | 2,089 |
Total current assets | 130,643 | 149,209 |
Property and equipment, net | 105 | 1,699 |
Other assets | 261 | 2,324 |
Total assets | 131,009 | 153,232 |
Current liabilities: | ||
Accounts payable | 508 | 1,128 |
Accrued expenses and other current liabilities | 5,461 | 4,187 |
Total current liabilities | 5,969 | 5,315 |
Other long term liabilities | 9 | 1,631 |
Total liabilities | 5,978 | 6,946 |
Commitments and Contingencies (Note 10) | ||
Stockholders' equity: | ||
Preferred stock, $0.001 par value: 40,000,000 shares authorized as of September 30, 2023 and December 31, 2022; no shares issued and outstanding as of September 30, 2023 and December 31, 2022 | ||
Common stock, $0.001 par value: 280,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 36,091,075 and 35,575,694 shares issued as of September 30, 2023 and December 31, 2022, respectively; 36,083,742 and 35,516,249 shares outstanding as of September 30, 2023 and December 31, 2022, respectively | 35 | 35 |
Additional paid-in capital | 287,532 | 284,365 |
Accumulated deficit | (162,536) | (138,114) |
Total stockholders' equity | 125,031 | 146,286 |
Total liabilities and stockholders' equity | $ 131,009 | $ 153,232 |